FR2942227B1 - Utilisation de tampons pour la complexation de radionucleides - Google Patents

Utilisation de tampons pour la complexation de radionucleides

Info

Publication number
FR2942227B1
FR2942227B1 FR0950944A FR0950944A FR2942227B1 FR 2942227 B1 FR2942227 B1 FR 2942227B1 FR 0950944 A FR0950944 A FR 0950944A FR 0950944 A FR0950944 A FR 0950944A FR 2942227 B1 FR2942227 B1 FR 2942227B1
Authority
FR
France
Prior art keywords
complexation
radionuclide
carboxylic acid
function
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0950944A
Other languages
English (en)
Other versions
FR2942227A1 (fr
Inventor
Marc Port
Christelle Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0950944A priority Critical patent/FR2942227B1/fr
Application filed by Guerbet SA filed Critical Guerbet SA
Priority to US13/201,115 priority patent/US20120009124A1/en
Priority to EP10703282.3A priority patent/EP2396040B1/fr
Priority to JP2011549557A priority patent/JP2012517974A/ja
Priority to PCT/EP2010/051709 priority patent/WO2010092114A1/fr
Priority to KR1020117021102A priority patent/KR20110115606A/ko
Priority to CA2752181A priority patent/CA2752181C/fr
Priority to CN201080010448.1A priority patent/CN102341127B/zh
Publication of FR2942227A1 publication Critical patent/FR2942227A1/fr
Application granted granted Critical
Publication of FR2942227B1 publication Critical patent/FR2942227B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System

Abstract

La présente invention concerne un procédé de complexation d'un chélate par un radionucléide, avantageusement le Gallium la complexation étant réalisé, avantageusement à température ambiante sans chauffage, en additionnant le radionucléide au chélate dans une solution tampon, le tampon de cette solution comprenant entre deux et cinq fonctions de coordination avec le radionucléide, chaque fonction de coordination étant indépendamment choisie parmi une fonction acide carboxylique et une fonction hydroxy, à la condition que le tampon comprenne au moins une fonction acide carboxylique et au plus deux fonctions acide carboxylique. Elle concerne également la solution injectable obtenue.
FR0950944A 2009-02-13 2009-02-13 Utilisation de tampons pour la complexation de radionucleides Expired - Fee Related FR2942227B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0950944A FR2942227B1 (fr) 2009-02-13 2009-02-13 Utilisation de tampons pour la complexation de radionucleides
EP10703282.3A EP2396040B1 (fr) 2009-02-13 2010-02-11 Utilisation de tampons pour la complexation de radionucléides
JP2011549557A JP2012517974A (ja) 2009-02-13 2010-02-11 放射性核種錯化のための緩衝剤の使用
PCT/EP2010/051709 WO2010092114A1 (fr) 2009-02-13 2010-02-11 Utilisation de tampons pour la complexation de radionucléides
US13/201,115 US20120009124A1 (en) 2009-02-13 2010-02-11 Use of buffers for radionuclide complexation
KR1020117021102A KR20110115606A (ko) 2009-02-13 2010-02-11 방사성 핵종 착화에 있어서 완충액의 용도
CA2752181A CA2752181C (fr) 2009-02-13 2010-02-11 Utilisation de tampons pour la complexation de radionucleides
CN201080010448.1A CN102341127B (zh) 2009-02-13 2010-02-11 缓冲剂用于放射性核素络合的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0950944A FR2942227B1 (fr) 2009-02-13 2009-02-13 Utilisation de tampons pour la complexation de radionucleides

Publications (2)

Publication Number Publication Date
FR2942227A1 FR2942227A1 (fr) 2010-08-20
FR2942227B1 true FR2942227B1 (fr) 2011-04-15

Family

ID=40873380

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0950944A Expired - Fee Related FR2942227B1 (fr) 2009-02-13 2009-02-13 Utilisation de tampons pour la complexation de radionucleides

Country Status (8)

Country Link
US (1) US20120009124A1 (fr)
EP (1) EP2396040B1 (fr)
JP (1) JP2012517974A (fr)
KR (1) KR20110115606A (fr)
CN (1) CN102341127B (fr)
CA (1) CA2752181C (fr)
FR (1) FR2942227B1 (fr)
WO (1) WO2010092114A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
CN103370063A (zh) * 2010-12-13 2013-10-23 免疫医疗公司 用于改善蛋白质、肽和其他分子的f-18标记的方法和组合物
ITFI20110180A1 (it) * 2011-08-12 2013-02-13 Advanced Accelerator Applic S A Processo per la preparazione di complessi di 68ga.
FR2980193B1 (fr) * 2011-09-15 2014-02-14 Guerbet Sa Procede de purification de produits de contraste
WO2013086396A1 (fr) * 2011-12-09 2013-06-13 Ikaria Development Subsidiary One Llc Conjugués d'alginates marqués pour des applications d'imagerie moléculaire
US8658580B2 (en) 2012-03-01 2014-02-25 Uchicago Argonne, Llc Superabsorbing gel for actinide, lanthanide, and fission product decontamination
CN102709192A (zh) * 2012-06-21 2012-10-03 复旦大学 一种集成阻变存储器的mos晶体管结构的制造方法
US20150004103A1 (en) * 2013-06-28 2015-01-01 Bbs Nanotechnology Ltd. Tumorspecific PET/MR(T1), PET/MR(T2) and PET/CT contrast agent
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
BE1021191B1 (fr) * 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
JP7104274B2 (ja) * 2016-08-19 2022-07-21 Ｐｄｒファーマ株式会社 緩衝剤を含む組成物
US10016520B1 (en) 2017-01-09 2018-07-10 SeeCure Taiwan Co., Ltd. Compound and pharmaceutical composition for tumor imaging and tumor therapy
IT201800002279A1 (it) * 2018-01-31 2019-07-31 Azienda Usl Di Reggio Nellemilia Sintesi di derivati della curcumina con un gruppo chelante per la complessazione di metalli e radionuclidi
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
JP2023510306A (ja) * 2020-01-10 2023-03-13 フュージョン ファーマシューティカルズ インコーポレイテッド 大環状キレートおよびその使用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395946A (en) * 1988-02-09 1995-03-07 Goedemans; Wilhelmus T. Bifunctional chelating agents
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
WO1994005269A1 (fr) 1992-09-08 1994-03-17 Centocor, Inc. Inhibiteurs peptidiques de fixation de la selectine
ES2156143T3 (es) 1993-12-30 2001-06-16 Guerbet Sa Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas.
US5476644A (en) * 1994-04-13 1995-12-19 Sterling Winthrop Inc. Cyclic triamine chelating agents
DE19505960A1 (de) 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
NZ500273A (en) 1997-03-18 2001-12-21 Nihon Schering Kabushiki Kaish Gadolinium (Gd) polymer MRI contrast agent responsive to environmental changes
WO1999040947A2 (fr) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Molecules ciblant l'angiogenese
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
EP1054871A2 (fr) 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Antagonistes de l'integrine
CA2326978A1 (fr) 1998-04-03 1999-10-14 Milind Rajopadhye Produits radiopharmaceutiques pour visualiser des infections et des inflammations et pour visualiser et traiter le cancer
WO1999054317A1 (fr) 1998-04-23 1999-10-28 Cortech Inc. Inhibiteurs de cysteine proteases
AU6422299A (en) 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Chelator incorporated arg-gly-asp (rgd) mimetic synthetic disintegrins as imaging agents
US6511648B2 (en) 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP4682313B2 (ja) 1999-01-19 2011-05-11 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 感染及び炎症をターゲティング及び撮像するための化合物
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
TWI290146B (en) 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
WO2001010450A1 (fr) 1999-08-10 2001-02-15 Imarx Therapeutics, Inc. Agents thrombolytiques cibles
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6534038B2 (en) 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
DE60111733T2 (de) 2000-04-12 2006-05-18 Amersham Health As Integrinbindende peptidderivate
CA2412849A1 (fr) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
AU7002501A (en) 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
MEP13708A (en) 2000-06-23 2010-06-10 Bayer Schering Pharma Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002032292A2 (fr) 2000-10-18 2002-04-25 The Board Of Trustess Of The Leland Stanford Junior University Procedes pour la mise au point et l'utilisation d'agents diagnostiques et therapeutiques
WO2002040060A2 (fr) 2000-10-31 2002-05-23 Bracco International Bv Conjugues d'antioxydants et de ligands de chelation metallique destines a des applications diagnostiques et therapeutiques
EP1343758A1 (fr) 2000-11-08 2003-09-17 K.U. Leuven Research & Development Derives de bis-indole substitue utilises comme agents de contraste, compositions pharmaceutiques contenant lesdits derives et intermediaires permettant de preparer ces derives
JP2005506952A (ja) 2000-11-27 2005-03-10 ブリストル−マイヤーズ・スクイブ・メディカル・イメージング・インコーポレイテッド 心臓潅流およびビトロネクチンレセプター標的造影剤の同時造影
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
WO2002062810A2 (fr) 2000-11-29 2002-08-15 Bracco International B.V. Analogues de sialyl lewis x susceptibles de se lier
US7105530B2 (en) 2000-12-21 2006-09-12 Smithkline Beecham Corporation Pyrimidineamines as angiogenesis modulators
WO2002056670A2 (fr) 2001-01-05 2002-07-25 The General Hospital Corporation Sondes d'imagerie activables
EP1379885A4 (fr) 2001-01-05 2005-07-06 Univ Duke Agent ameliorateur de contraste en imagerie par resonance magnetique
CA2432932A1 (fr) 2001-02-16 2002-08-29 Mark A. Scialdone Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation
EP1365813A4 (fr) * 2001-02-26 2006-03-22 Bristol Myers Squibb Pharma Co Analogues a l'acide ascorbique pour produits metalloradiopharmaceutiques
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
AU2002307146B2 (en) 2001-04-04 2007-02-01 University Of Rochester AlphaNuBeta3 integrin-binding polypeptide monobodies and their use
ES2274973T3 (es) 2001-04-23 2007-06-01 The Trustees Of The University Of Pennsylvania Inhibidores de la agregacion de placas amiloides y agentes de obtencion de imagenes diagnosticas.
WO2002085908A1 (fr) 2001-04-24 2002-10-31 Purdue Research Foundation Mimetiques de folate et ses conjugues de liaison aux recepteurs de folate
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US20040241160A1 (en) 2001-07-13 2004-12-02 Yan Wu Vegfr-1 antibodies to treat breast cancer
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
AU2002336959B2 (en) 2001-08-10 2006-07-13 Novartis Ag Peptides that bind to atherosclerotic lesions
US7338651B2 (en) 2001-09-04 2008-03-04 Texas Tech University System Multi-use multimodal imaging chelates
MXPA04007188A (es) 2002-01-24 2005-10-18 Barnes Jewish Hospital Agentes para imagen dirigidos a integrina.
GB0308408D0 (en) * 2003-04-11 2003-05-21 Amersham Plc Microwave activation
GB0314695D0 (en) * 2003-06-24 2003-07-30 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
US20070269375A1 (en) 2003-07-24 2007-11-22 Bracco Imaging S.P.A. Stable Radiopharmaceutical Compositions and Methods for Preparation
FR2875410B1 (fr) 2004-09-23 2012-11-16 Guerbet Sa Composes de diagnostique pour le ciblage de recpteur a chimiokines
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
CA2625196C (fr) * 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
KR20150140415A (ko) * 2007-04-11 2015-12-15 메르크 앤드 씨에 진단 이미징 및 방사선치료에 사용하기 위한 폴레이트-컨쥬게이트 및 대응하는 금속-킬레이트 착물

Also Published As

Publication number Publication date
CN102341127A (zh) 2012-02-01
EP2396040A1 (fr) 2011-12-21
KR20110115606A (ko) 2011-10-21
CN102341127B (zh) 2014-08-27
CA2752181A1 (fr) 2010-08-19
CA2752181C (fr) 2018-03-06
EP2396040B1 (fr) 2017-04-05
US20120009124A1 (en) 2012-01-12
FR2942227A1 (fr) 2010-08-20
WO2010092114A1 (fr) 2010-08-19
JP2012517974A (ja) 2012-08-09

Similar Documents

Publication Publication Date Title
FR2942227B1 (fr) Utilisation de tampons pour la complexation de radionucleides
FR2962738B1 (fr) Composition adhesive comprenant du chitosane desacetyle
MA31918B1 (fr) Agents et épitopes de liaison à wise
GB2497037A (en) Universal coupler for a beam blade windshield wiper assembly
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
AU2010246102A8 (en) Pesticidal compositions
EP2684788A3 (fr) Système de frein d'interverrouillage de véhicule de type califourchon et ledit véhicule
WO2009009756A3 (fr) Désactivateurs à base d'acide borique et de polyviologène utilisables dans les détecteurs d'analyte
WO2010052533A8 (fr) Système de diagnostic de batterie de véhicule
EA201170168A1 (ru) Комплекс (минерал-аминокислота)-полисахарид
WO2008125589A3 (fr) Complexes métalliques de tris(hétérocyclyle) en tant que catalyseurs de blanchiment
WO2010096336A3 (fr) Catalyseur de reformage
DK2175767T3 (da) Opvaskemaskine
TW200722858A (en) Backlight module and liquid crystal display device using the same
DK2084332T3 (da) System til montering af en rambuk
ATE554674T1 (de) Haftverschlussteil
WO2009088939A3 (fr) Compositions et procédés pour traiter des maladies neurodégénératives
FR2937880B1 (fr) Procede de conversion des composes soufres presents dans un gaz acide en soufre elementaire.
RU2007112594A (ru) Производные гиалуроновой кислоты с пониженной биодеградируемостью
MX2009003428A (es) Dispositivo de reduccion de la temperatura de escape para dispositivos de tratamiento.
MX357490B (es) Elemento estructural para un cierre de botellas con medios para evidenciar su primer uso en condiciones nominales.
FR3041350B1 (fr) Electrolyte solide pour generateur electrochimique
Kotulla et al. A Fast On-the-fly Data Reduction Pipeline for Rapid Inspection of pODI Data
FR2982830B1 (fr) Dispositif de renforcement d'un tablier de vehicule, adaptable en fonction de son poste d'implantation
TR200805807U (tr) Çelik kapılarda kancalı güvenlik uygulaması

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20211005